Antiviral therapy for human rabies

Antiviral Therapy

Volumn 20, Issue 1, 2015, Pages 1-10

  Appolinario, Camila M ^a   Jackson, Alan C ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; FAVIPIRAVIR; KETAMINE; MINOCYCLINE; RIBAVIRIN; STEROID; UBIQUITIN PROTEIN LIGASE NEDD4; AMIDE; CORTICOSTEROID; IMMUNOLOGIC FACTOR; NEUROPROTECTIVE AGENT; PYRAZINE DERIVATIVE; SMALL INTERFERING RNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOTHERAPY; NEUROPROTECTION; PATHOGENESIS; POST EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; RABIES; REVIEW; RNA INTERFERENCE; VIRUS RELEASE; ANIMAL; CONTRAINDICATIONS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PATHOGENICITY; PATHOLOGY; RABIES VIRUS; VIROLOGY; VIRUS ASSEMBLY;

ADRENAL CORTEX HORMONES; AMIDES; ANIMALS; ANTIVIRAL AGENTS; CENTRAL NERVOUS SYSTEM; COMBINED MODALITY THERAPY; HUMANS; IMMUNOLOGIC FACTORS; MINOCYCLINE; MOLECULAR TARGETED THERAPY; NEUROPROTECTIVE AGENTS; PYRAZINES; RABIES; RABIES VIRUS; RNA, SMALL INTERFERING; VIRUS ASSEMBLY; VIRUS RELEASE;

EID: 84927710697     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2851     Document Type: Review

References (91)

1. Jackson AC. Therapy of human rabies. In Jackson AC (Editor). Rabies: scientific basis of the disease and its management. Third Edition. Oxford, UK: Elsevier Academic Press 2013; pp. 573-587.
2. Jackson AC. Recovery from rabies: a call to arms. J Neurol Sci 2014; 339:5-7.
3. Jackson AC. Current and future approaches to the therapy of human rabies. Antiviral Res 2013; 99:61-67.
4. Jackson AC, Fu ZF. Pathogenesis. In Jackson AC (Editor). Rabies: scientific basis of the disease and its management. Third Edition. Oxford, UK: Elsevier Academic Press 2013; pp. 299-349.
5. Jackson AC. Human disease. In Jackson AC (Editor). Rabies: scientific basis of the disease and its management. Third Edition. Oxford, UK: Elsevier Academic Press 2013; pp. 269-298.
6. Stockwell J, Abdi N, Lu X, Maheshwari O, Taghibiglou C. Novel central nervous system drug delivery systems. Chem Biol Drug Des 2014; 83:507-520.
7. Bartanusz V, Jezova D, Alajajian B, Digicaylioglu M. The blood-spinal cord barrier: morphology and clinical implications. Ann Neurol 2011; 70:194-206.
8. Bentivoglio M, Kristensson K. Tryps and trips: cell trafficking across the 100-year-old blood-brain barrier. Trends Neurosci 2014; 37:325-333.
9. Anand BS, Dey S, Mitra AK. Current prodrug strategies via membrane transporters/receptors. Expert Opin Biol Ther 2002; 2:607-620.
10. Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 2012; 64:686-700.
11. Vyas TK, Tiwari SB, Amiji MM. Formulation and physiological factors influencing CNS delivery upon intranasal administration. Crit Rev Ther Drug Carrier Syst 2006; 23:319-347.
12. van Woensel M, Wauthoz N, Rosiere R, et al. Formulations for intranasal delivery of pharmacological agents to combat brain disease: a new opportunity to tackle GBM? Cancers (Basel) 2013; 5:1020-1048.
13. Colombo G, Lorenzini L, Zironi E, et al. Brain distribution of ribavirin after intranasal administration. Antiviral Res 2011; 92:408-414.
14. Tsutsui JM, Xie F, Porter RT. The use of microbubbles to target drug delivery. Cardiovasc Ultrasound 2004; 2:23.
15. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6:1375-1379.
16. Martin P, Jensen DM. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 2008; 23:844-855.
17. McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314:20-26.
18. Weisman LE. Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future. Cardiovasc Hematol Agents Med Chem 2009; 7:223-233.
19. Bussereau F, Chermann JC, De Clercq E, Hannoun C. Search for compounds which have an inhibitory effect on rhabdovirus multiplication in vitro. Annales de l'Institut Pasteur/Virologie 1983; 134:127-134.
20. Bussereau F, Ermine A. Effects of heteropolyanions and nucleoside analogues on rabies virus: in vitro study of syntheses and viral production. Annales de l'Institut Pasteur/Virologie 1983; 134:487-506.
21. Appolinario CM, Prehaud C, Allendorf SD, et al. Ribavirin has an in vitro antiviral effect in rabies virus infected neuronal cells but fails to provide benefit in experimental rabies in mice. J Virol Antivir Res 2013; doi: 10.4172/2324-8955.1000111.
22. Bussereau F, Picard M, Blancou J, Sureau P. Treatment of rabies in mice and foxes with antiviral compounds. Acta Virol 1988; 32:33-49.
23. Warrell MJ, White NJ, Looareesuwan S, et al. Failure of interferon alfa and tribavirin in rabies encephalitis. BMJ 1989; 299:830-833.
24. Kureishi A, Xu LZ, Wu H, Stiver HG. Rabies in China: recommendations for control. Bull World Health Organ 1992; 70:443-450.
25. Swanson D, Feigin R, Tanney L, et al. Human rabies - Texas. MMWR Morb Mortal Wkly Rep 1984; 33:469-470.
26. Powers CN, Peavy DL, Knight V. Selective inhibition of functional lymphocyte subpopulations by ribavirin. Antimicrob Agents Chemother 1982; 22:108-114.
27. Reinke SN, Resch L, Maingut F, et al. Metagenomic and metabolomic characterization of rabies encephalitis: new insights into the treatment of an ancient disease. J Infect Dis 2013; 207:1451-1456.
28. Willoughby RE, Jr., Tieves KS, Hoffman GM, et al. Survival after treatment of rabies with induction of coma. N Engl J Med 2005; 352:2508-2514.
29. Willoughby RE, Jr. Are we getting closer to the treatment of rabies? Future Virology 2009; 4:563-570.
30. Chopy D, Detje CN, Lafage M, Kalinke U, Lafon M. The type I interferon response bridles rabies virus infection and reduces pathogenicity. J Neurovirol 2011; 17:353-367.
31. Dacheux L, Delmas O, Bourhy H. Human rabies encephalitis prevention and treatment: progress since Pasteur's discovery. Infect Disord Drug Targets 2011; 11:251-299.
32. Niu X, Tang L, Tseggai T, Guo Y, Fu ZF. Wild-type rabies virus phosphoprotein is associated with viral sensitivity to type I interferon treatment. Arch Virol 2013; 158:2297-2305.
33. Baer GM, Shaddock JH, Moore SA, Yager PA, Baron SS, Levy HB. Successful prophylaxis against rabies in mice and rhesus monkeys: the interferon system and vaccine. J Infect Dis 1977; 136:286-291.
34. Harmon MW, Janis B. Therapy of murine rabies after exposure: efficacy of polyriboinosinic-polyribocytidylic acid alone and in combination with three rabies vaccines. J Infect Dis 1975; 132:241-249.
35. Weinmann E, Majer M, Hilfenhaus J. Intramuscular and/or intralumbar postexposure treatment of rabies virus-infected cynomolgus monkeys with human interferon. Infect Immun 1979; 24:24-31.
36. Merigan TC, Baer GM, Winkler WG, et al. Collaborative Group. Human leukocyte interferon administration to patients with symptomatic and suspected rabies. Ann Neurol 1984; 16:82-87.
37. Lockhart BP, Tsiang H, Ceccaldi PE, Guillemer S. Ketamine-mediated inhibition of rabies virus infection in vitro and in rat brain. Antivir Chem Chemother 1991; 2:9-15.
38. Weli SC, Scott CA, Ward CA, Jackson AC. Rabies virus infection of primary neuronal cultures and adult mice: failure to demonstrate evidence of excitotoxicity. J Virol 2006; 80:10270-10273.
39. Wilson RD, Priano LL, Traber DL, Sakai H, Daniels JC, Ritzmann SE. An investigation of possible immunosuppression from ketamine and 100 percent oxygen in normal children. Anesth Analg 1971; 50:464-470.
40. Freire-Garabal M, Belmonte A, Balboa JL, Nunez MJ. Effects of midazolam on T-cell immunosuppressive response to surgical stress in mice. Pharmacol Biochem Behav 1992; 43:85-89.
41. Galley HF, Dubbels AM, Webster NR. The effect of midazolam and propofol on interleukin-8 from human polymorphonuclear leukocytes. Anesth Analg 1998; 86:1289-1293.
42. Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 2005; 25:3312-3322.
43. Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson's disease. Cochrane Database Syst Rev 2003; CD003468.
44. Superti F, Seganti L, Pana A, Orsi N. Effect of amantadine on rhabdovirus infection. Drugs Exp Clin Res 1985; 11:69-74.
45. Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005; 293:2003-2011.
46. Jackson AC. Is minocycline useful for therapy of acute viral encephalitis? Antiviral Res 2012; 95:242-244.
47. Jackson AC, Scott CA, Owen J, Weli SC, Rossiter J P. Therapy with minocycline aggravates experimental rabies in mice. J Virol 2007; 81:6248-6253.
48. Jackson AC, Warrell MJ, Rupprecht CE, et al. Management of rabies in humans. Clin Infect Dis 2003; 36:60-63.
49. Enright JB, Franti CE, Frye FL, Behymer DE. The effects of corticosteroids on rabies in mice. Can J Microbiol 1970; 16:667-675.
50. Enright JB, Goggin JE, Frye FL, Franti CE, Behymer DE. Effects of corticosteroids on rabies virus infections in various animal species. J Am Vet Med Assoc 1970; 156:765-769.
51. Basgoz N, Frosch MP. Case records of the Massachusetts General Hospital: a 32-year-old woman with pharyngeal spasms and paresthesias after a dog bite. N Engl J Med 1998; 339:105-112.
52. Neuwelt EA, Barnett PA, Bigner DD, Frenkel EP. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci U S A 1982; 79:4420-4423.
53. Roy, A, Hooper DC. Lethal silver-haired bat rabies virus infection can be prevented by opening the blood-brain barrier. J Virol 2007; 81:7993-7998.
54. Bray M. Highly pathogenic RNA viral infections: challenges for antiviral research. Antiviral Res 2008; 78:1-8.
55. Leyssen P, De Clercq E, Neyts J. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res 2008; 78:9-25.
56. Öberg B. Rational design of polymerase inhibitors as antiviral drugs. Antiviral Res 2006; 71:90-95.
57. Spurgers KB, Sharkey CM, Warfield KL, Bavari S. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008; 78:26-36.
58. Liang HR, Hu GQ, Li L, Gao YW, Yang ST, Xia XZ. Aptamers targeting rabies virus-infected cells inhibit street rabies virus in vivo. Int Immunopharmacol 2014; 21:432-438.
59. Furuta Y, Takahashi K, Shiraki K, et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009; 82:95-102.
60. Morrey JD, Taro BS, Siddharthan V, et al. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 2008; 80:377-379.
61. Kiso M, Takahashi K, Sakai-Tagawa Y, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A 2010; 107:882-887.
62. Mendenhall M, Russell A, Smee DF, et al. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLoS Negl Trop Dis 2011; 5:e1342.
63. Buys KK, Jung KH, Smee DF, Furuta Y, Gowen BB. Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir. Antivir Chem Chemother 2011; 21:193-200.
64. Julander JG, Smee DF, Morrey JD, Furuta Y. Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Res 2009; 82:169-171.
65. Meshram CD, Singh NK, Sonwane AA, et al. Evaluation of single and dual siRNAs targeting rabies virus glycoprotein and nucleoprotein genes for inhibition of virus multiplication in vitro. Arch Virol 2013; 158:2323-2332.
66. Gupta PK, Sonwane AA, Singh NK, et al. Intracerebral delivery of small interfering RNAs (siRNAs) using adenoviral vector protects mice against lethal peripheral rabies challenge. Virus Res 2012; 163:11-18.
67. Yang YJ, Zhao PS, Zhang T, et al. Small interfering RNAs targeting the rabies virus nucleoprotein gene. Virus Res 2012; 169:169-174.
68. Brandão PE, Castilho JG, Fahl W, et al. Short-interfering RNAs as antivirals against rabies. Braz J Infect Dis 2007; 11:224-225.
69. Israsena N, Supavonwong P, Ratanasetyuth N, Khawplod P, Hemachudha T. Inhibition of rabies virus replication by multiple artificial microRNAs. Antiviral Res 2009; 84:76-83.
70. Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007; 448:39-43.
71. Kumar P, Lee SK, Shankar P, Manjunath N. A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med 2006; 3:e96.
72. Han Z, Lu J, Liu Y, et al. Small molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses. J Virol 2014; 88:7294-7306.
73. Lingappa UF, Wu X, Macieik A, et al. Host-rabies virus protein-protein interactions as druggable antiviral targets. Proc Natl Acad Sci U S A 2013; 110:E861-E868.
74. Becker T, Franckenberg S, Wickles S, et al. Structural basis of highly conserved ribosome recycling in eukaryotes and archaea. Nature 2012; 482:501-506.
75. Zimmerman C, Klein KC, Kiser PK, et al. Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature 2002; 415:88-92.
76. Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57:1-28.
77. World Health Organization. WHO expert consultation on rabies: second report (WHO technical report series; no. 982). Geneva: World Health Organization 2013.
78. Rupprecht CE, Briggs D, Brown CM, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2010; 59:1-9.
79. Hicks DJ, Fooks AR, Johnson N. Developments in rabies vaccines. Clin Exp Immunol 2012; 169:199-204.
80. Wunner WH. Rabies viruses - pathogenesis and immunity. In Wagner RR (Editor). The rhabdoviruses. New York: Plenum Press 1987; pp. 361-426.
81. Lafon M. Immunology. In Jackson AC (Editor). Rabies: scientific basis of the disease and its management. Third Edition. Oxford, UK: Elsevier Academic Press 2013; pp. 387-408.
82. Miller DW. Immunobiology of the blood-brain barrier. J Neurovirol 1999; 5:570-578.
83. Montaner AD, De Nichilo A, Rodriguez JM, et al. IMT504: a new and potent adjuvant for rabies vaccines permitting significant dose sparing. World Journal of Vaccines 2012; 2:182-188.
84. Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C. Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int J Stroke 2012; 7:407-418.
85. Jackson AC, Kammouni W, Zherebitskaya E, Fernyhough P. Role of oxidative stress in rabies virus infection of adult mouse dorsal root ganglion neurons. J Virol 2010; 84:4697-4705.
86. Alandijany T, Kammouni W, Roy Chowdhury SK, Fernyhough P, Jackson AC. Mitochondrial dysfunction in rabies virus infection of neurons. J Neurovirol 2013; 19:537-549.
87. Jackson AC, Kammouni W, Wood H, et al. Role of the rabies virus phosphoprotein in the induction of mitochondrial dysfunction in rabies virus infection. 16th International Congress on Infectious Diseases. 5 April 2014, Cape Town, South Africa. Abstract 64.009.
88. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002; 346:557-563.
89. The Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002; 346:549-556.
90. Little NE, Feldman EL. Therapeutic hypothermia after cardiac arrest without return of consciousness: skating on thin ice. JAMA Neurol 2014; 71:823-824.
91. Lampe JW, Becker LB. State of the art in therapeutic hypothermia. Annu Rev Med 2011; 62:79-93.